Table 1.
Demographic and clinical characteristics of the study patients according to monthly purchases of ACEIs/ARBs
| All Patients | Purchased 4–6 Monthly Prescriptions per Year (n=1278) | Purchased ≥7 Monthly Prescriptions per Year (n=7816) | P Value | |
|---|---|---|---|---|
| Age, y | 59.7±7.4 | 58.6 ±8.0 | 59.9±7.2 | <.001 |
| Men, % | 51.1 | 52.4 | 50.9 | .22 |
| Low socioeconomic status, % | 36.6 | 40.9 | 35.9 | <.001 |
| BMI | 30.5±5.8 | 29.9±5.8 | 30.6±5.7 | <.001 |
| Systolic blood pressure | 141.3±20.1 | 139.5±20.5 | 141.6±20.0 | <.001 |
| Glycated hemoglobin at start | 8.5±2.0 | 8.9±2.3 | 8.4±2.0 | <.001 |
| eGFR at start | 67.9±16.8 | 70.3±17.1 | 67.5±16.7 | <.001 |
| Hypertension, % | 61.6 | 45.7 | 64.1 | <.001 |
| Ischemic heart disease, % | 22.3 | 17.7 | 23.1 | <.001 |
| Past cerebrovascular accident, % | 6.6 | 7.3 | 6.5 | .29 |
| Smoking, % | 39.6 | 41.2 | 39.3 | .20 |
| Insulin use, % | 16.3 | 14.0 | 16.7 | .01 |
Abbreviations: ACEIs, angiotensin‐converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BMI, body mass index; eGFR, estimated glomerular filtration rate.